BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, Filali-Mouhim A, Goulet JP, Loof NM, Ossendorp F, Perdiguero B, Heinen P, Gomez CE, Kibler KV, Koelle DM, Sékaly RP, Sallusto F, Lanzavecchia A, Pantaleo G, Esteban M, Tartaglia J, Jacobs BL, Melief CJ. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 2011;6:e16819. [PMID: 21347234 DOI: 10.1371/journal.pone.0016819] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 García-Arriaza J, Arnáez P, Gómez CE, Sorzano CÓ, Esteban M. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One 2013;8:e66894. [PMID: 23826170 DOI: 10.1371/journal.pone.0066894] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
2 Yu J, Li Y, Zhong M, Yang J, Zhou D, Zhao B, Cao Y, Yan H, Zhang E, Yang Y, Feng Z, Qi X, Yan H. Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan. Antiviral Research 2018;153:49-59. [DOI: 10.1016/j.antiviral.2018.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lousberg EL, Diener KR, Brown MP, Hayball JD. Innate immune recognition of poxviral vaccine vectors. Expert Rev Vaccines 2011;10:1435-49. [PMID: 21988308 DOI: 10.1586/erv.11.121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
4 Meador LR, Mor TS. Meeting report VLPNPV: Session 5: Plant based technology. Hum Vaccin Immunother 2014;10:3068-73. [PMID: 25581535 DOI: 10.4161/21645515.2014.979693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Haddad EK, Pantaleo G. Systems biology in the development of HIV vaccines. Curr Opin HIV AIDS 2012;7:44-9. [PMID: 22156842 DOI: 10.1097/COH.0b013e32834ddcc3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, Holechek S, Arndt W, Jimenez V, Gonzalez-Sanz R, Denzler K, Haddad EK, Wagner R, Sékaly RP, Tartaglia J, Pantaleo G, Jacobs BL, Esteban M. Improved NYVAC-based vaccine vectors. PLoS One 2011;6:e25674. [PMID: 22096477 DOI: 10.1371/journal.pone.0025674] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
7 Parks C. Replication-Competent Viral Vectors for Vaccine Delivery. Human Vaccines. Elsevier; 2017. pp. 25-63. [DOI: 10.1016/b978-0-12-802302-0.00001-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, Silva AL, Jiskoot W, van Hall T, van Veelen PA. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol. 2013;43:2554-2565. [PMID: 23836147 DOI: 10.1002/eji.201343324] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 10.7] [Reference Citation Analysis]
9 Kibler KV, Szczerba M, Lake D, Roeder AJ, Rahman M, Hogue BG, Roy Wong LY, Perlman S, Li Y, Jacobs BL. Intranasal Immunization with a Vaccinia Virus Vaccine Vector Expressing Pre-Fusion Stabilized SARS-CoV-2 Spike Fully Protected Mice against Lethal Challenge with the Heavily Mutated Mouse-Adapted SARS2-N501YMA30 Strain of SARS-CoV-2. Vaccines (Basel) 2022;10:1172. [PMID: 35893821 DOI: 10.3390/vaccines10081172] [Reference Citation Analysis]
10 Gómez CE, Perdiguero B, Jiménez V, Filali-Mouhim A, Ghneim K, Haddad EK, Quakkelaar ED, Delaloye J, Harari A, Roger T, Duhen T, Sékaly RP, Melief CJ, Calandra T, Sallusto F, Lanzavecchia A, Wagner R, Pantaleo G, Esteban M. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One 2012;7:e35485. [PMID: 22536391 DOI: 10.1371/journal.pone.0035485] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
11 Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, Marshak JO, McClurkan CL, Yamamoto TN, Bailer SM, Laing KJ, Wald A, Verjans GM, Koelle DM. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest 2012;122:654-73. [PMID: 22214845 DOI: 10.1172/JCI60556] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
12 Mooij P, Koopman G, Drijfhout JW, Nieuwenhuis IG, Beenhakker N, Koestler J, Bogers WMJM, Wagner R, Esteban M, Pantaleo G, Heeney JL, Jacobs BL, Melief CJM. Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. J Gen Virol 2015;96:1478-83. [PMID: 25667320 DOI: 10.1099/vir.0.000074] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
13 Meador LR, Kessans SA, Kilbourne J, Kibler KV, Pantaleo G, Roderiguez ME, Blattman JN, Jacobs BL, Mor TS. A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. Virology 2017;507:242-56. [PMID: 28458036 DOI: 10.1016/j.virol.2017.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
14 Sui Y, Gordon S, Franchini G, Berzofsky JA. Nonhuman primate models for HIV/AIDS vaccine development. Curr Protoc Immunol 2013;102:12.14.1-12.14.30. [PMID: 24510515 DOI: 10.1002/0471142735.im1214s102] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
15 Delaloye J, Filali-Mouhim A, Cameron MJ, Haddad EK, Harari A, Goulet JP, Gomez CE, Perdiguero B, Esteban M, Pantaleo G, Roger T, Sékaly RP, Calandra T. Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins. J Virol 2015;89:3819-32. [PMID: 25609807 DOI: 10.1128/JVI.03061-14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
16 Zhang Q, Liu Z, Hou J, Wang S, Liu C, Wei M, Liu Y, Shao Y. Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system. Vaccine 2016;34:3447-53. [PMID: 27195760 DOI: 10.1016/j.vaccine.2016.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Lévy Y. Perpetuation of vaccine memory T cell responses against SIV/HIV. EMBO Mol Med 2011;3:507-9. [PMID: 21830302 DOI: 10.1002/emmm.201100163] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Musich T, Robert-Guroff M. New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. Expert Rev Vaccines 2016;15:1015-27. [PMID: 26910195 DOI: 10.1586/14760584.2016.1158108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yamamoto T, Johnson MJ, Price DA, Wolinsky DI, Almeida JR, Petrovas C, Nason M, Yeh WW, Shen L, Roederer M, Rao SS, McDermott AB, Lefebvre F, Nabel GJ, Haddad EK, Letvin NL, Douek DC, Koup RA. Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J Virol 2012;86:5877-84. [PMID: 22419810 DOI: 10.1128/JVI.00315-12] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
20 Tabachnick-Cherny S, Pulliam T, Church C, Koelle DM, Nghiem P. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. Mol Carcinog 2020;59:807-21. [PMID: 32219902 DOI: 10.1002/mc.23190] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
21 Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 2012;8:1192-207. [PMID: 22906946 DOI: 10.4161/hv.20778] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
22 Travieso T, Li J, Mahesh S, Mello JDFRE, Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines 2022;7:75. [PMID: 35787629 DOI: 10.1038/s41541-022-00503-y] [Reference Citation Analysis]
23 Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines. Viruses 2015;7:1726-803. [PMID: 25853483 DOI: 10.3390/v7041726] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 14.4] [Reference Citation Analysis]
24 Melamed S, Wyatt LS, Kastenmayer RJ, Moss B. Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. Vaccine 2013;31:4569-77. [PMID: 23928462 DOI: 10.1016/j.vaccine.2013.07.057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
25 Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013;31:3502-18. [PMID: 23707164 DOI: 10.1016/j.vaccine.2013.05.018] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 9.7] [Reference Citation Analysis]
26 Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, Esteban M. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 2012;86:5026-38. [PMID: 22419805 DOI: 10.1128/JVI.06684-11] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
27 Quakkelaar ED, Melief CJ. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol 2012;114:77-106. [PMID: 22449779 DOI: 10.1016/B978-0-12-396548-6.00004-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
28 Ryerson MR, Shisler JL. Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity. Virus Res 2018;246:55-64. [PMID: 29341877 DOI: 10.1016/j.virusres.2018.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 2012;7:e48524. [PMID: 23119046 DOI: 10.1371/journal.pone.0048524] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
30 Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol 2014;88:1809-14. [PMID: 24257612 DOI: 10.1128/JVI.02386-13] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
31 García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. J Virol 2017;91:e02182-16. [PMID: 28179536 DOI: 10.1128/JVI.02182-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
32 García-Arriaza J, Esteban M. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother 2014;10:2235-44. [PMID: 25424927 DOI: 10.4161/hv.28974] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
33 Rziha HJ, Rohde J, Amann R. Generation and Selection of Orf Virus (ORFV) Recombinants. Methods Mol Biol 2016;1349:177-200. [PMID: 26458837 DOI: 10.1007/978-1-4939-3008-1_12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
34 García-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, Yates NL, Shen X, Tomaras GD, Ferrari G, Foulds KE, McDermott A, Kao SF, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Wagner R, Ding S, Pantaleo G, Esteban M. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. J Virol 2015;89:8525-39. [PMID: 26041302 DOI: 10.1128/JVI.01265-15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
35 García-Arriaza J, Gómez CE, Sorzano CÓ, Esteban M. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol 2014;88:3392-410. [PMID: 24390336 DOI: 10.1128/JVI.02723-13] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
36 Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, Ambrozak DR, Sandler NG, Timmer KJ, Sun X, Pan L, Poholek A, Rao SS, Brenchley JM, Alam SM, Tomaras GD, Roederer M, Douek DC, Seder RA, Germain RN, Haddad EK, Koup RA. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012;122:3281-94. [PMID: 22922258 DOI: 10.1172/JCI63039] [Cited by in Crossref: 258] [Cited by in F6Publishing: 203] [Article Influence: 25.8] [Reference Citation Analysis]
37 Poland GA, Kennedy RB, McKinney BA, Ovsyannikova IG, Lambert ND, Jacobson RM, Oberg AL. Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin Immunol. 2013;25:89-103. [PMID: 23755893 DOI: 10.1016/j.smim.2013.04.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 8.1] [Reference Citation Analysis]
38 Parks CL, Picker LJ, King CR. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 2013;8:402-11. [PMID: 23925000 DOI: 10.1097/COH.0b013e328363d389] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 6.1] [Reference Citation Analysis]